FDA Approves DOXORUBICIN HYDROCHLORIDE — Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited announced on Friday, June 27, 2025, the approval of an ANDA by the U.S. FDA for doxorubicin hydrochloride injection, a generic version of the oncology treatment, positioning the company to further leverage its diversified portfolio and capture a share of the generic chemotherapeutic market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed